The Fort Worth Press - Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

USD -
AED 3.6725
AFN 64.498045
ALL 82.224051
AMD 357.911109
ANG 1.790403
AOA 917.999992
ARS 1552.245042
AUD 1.487498
AWG 1.8
AZN 1.701568
BAM 1.778889
BBD 2.013452
BDT 124.862431
BGN 1.77347
BHD 0.377187
BIF 3006.125762
BMD 1
BND 1.288366
BOB 11.661285
BRL 5.778103
BSD 0.999695
BTN 93.389482
BWP 13.993424
BYN 3.000114
BYR 19600
BZD 2.010633
CAD 1.430865
CDF 2294.000592
CHF 0.840555
CLF 0.025261
CLP 994.190035
CNY 6.66615
CNH 6.66805
COP 3309.02
CRC 445.311541
CUC 1
CUP 23.992906
CVE 100.292423
CZK 22.169932
DJF 178.024567
DKK 6.80141
DOP 60.539085
DZD 137.094024
EGP 53.720858
ERN 15
ETB 164.079674
EUR 0.90995
FJD 2.297898
FKP 0.756582
GBP 0.757725
GEL 2.590255
GGP 0.756582
GHS 11.730947
GIP 0.756582
GMD 74.000173
GNF 8857.115571
GTQ 7.640288
GYD 209.05242
HKD 7.845155
HNL 26.876953
HRK 6.831965
HTG 130.972791
HUF 333.799019
IDR 18254
ILS 3.254645
IMP 0.756582
INR 93.45245
IQD 1515.562185
IRR 1929053.503608
ISK 124.48026
JEP 0.756582
JMD 158.860526
JOD 0.709026
JPY 159.414008
KES 129.990105
KGS 87.449026
KHR 4078.347196
KMF 448.000085
KPW 900.00035
KRW 1329.397181
KWD 0.31169
KYD 0.833136
KZT 443.84516
LAK 22515.803356
LBP 89525.524706
LKR 332.648142
LRD 167.946083
LSL 16.912988
LTL 2.95274
LVL 0.60489
LYD 6.460474
MAD 9.977716
MDL 18.305023
MGA 4547.687046
MKD 56.015616
MMK 2099.387164
MNT 3606.75335
MOP 8.079605
MRU 40.508252
MUR 47.860043
MVR 15.433829
MWK 1733.487348
MXN 18.45096
MYR 4.098963
MZN 63.907732
NAD 16.912757
NGN 1350.869856
NIO 36.790956
NOK 9.637045
NPR 149.424033
NZD 1.82065
OMR 0.384524
PAB 0.999682
PEN 3.414253
PGK 4.497642
PHP 63.574997
PKR 276.397058
PLN 4.00875
PYG 6228.540504
QAR 3.644326
RON 4.867103
RSD 107.038986
RUB 82.204134
RWF 1479.544504
SAR 3.760904
SBD 8.137041
SCR 13.8922
SDG 601.498572
SEK 10.13571
SGD 1.289235
SHP 0.757117
SLE 22.801691
SLL 20969.503664
SOS 571.283045
SRD 37.437963
STD 20697.981008
STN 22.283565
SVC 8.747021
SYP 13002.000337
SZL 16.91126
THB 33.8665
TJS 9.212201
TMT 3.5
TND 3.02519
TOP 2.40776
TRY 50.441697
TTD 6.768777
TWD 32.958011
TZS 2650.003017
UAH 45.318338
UGX 4148.305798
UYU 40.61103
UZS 12014.188913
VES 915.501901
VND 25687
VUV 121.064676
WST 2.823281
XAF 596.887869
XAG 0.021752
XAU 0.0002631714
XCD 2.70255
XCG 1.801703
XDR 0.707052
XOF 596.887869
XPF 108.472418
YER 236.550078
ZAR 16.95717
ZMK 9001.196037
ZMW 20.479237
ZWL 321.999592
SSP 5928.707524
MXV 2.06991
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity.

Text size:

Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decline.

Dr. Laurent Mouchiroud, Chief Scientific Officer at Nagi Bioscience commented: "At Nagi Bioscience, we are thrilled to contribute to this groundbreaking study through our innovative microfluidic technology, which allows precise and automated monitoring of aging and healthspan metrics in real-time. These results highlight Telomir-1's remarkable potential to improve longevity and health, showcasing the power of cutting-edge tools in advancing age-reversal science."

By addressing the biological drivers of aging, Telomir-1 has the potential to profoundly impact patient care, offering new hope for managing and reversing age-related diseases while improving quality of life for countless individuals.

Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals, commented on the findings: "The results we are seeing with Telomir-1 mark an important step forward in our journey to potentially reverse aging in humans. This study confirms that Telomir-1 can reverse biological aging, extending life while preserving health. We are very excited about the potential applications of Telomir-1 as we progress toward human clinical trials."

Study Summary and Methodology

The preclinical study, conducted in collaboration with Nagi Bioscience SA, utilized a sophisticated in vivo microfluidic-based assay to assess the effects of Telomir-1 on the nematode Caenorhabditis elegans, a well-established model for aging studies. The microfluidic platform allowed precise, automated tracking of lifespan, healthspan, and age-related mobility decline in real-time, enabling the research team to accurately measure the effects of Telomir-1 on these critical metrics.

Two forms of Telomir-1 were administered in two concentrations, allowing the study to examine dose-dependent responses in treated subjects. The study found that Telomir-1 significantly enhanced lifespan and healthspan parameters in aged microorganism populations.

Key findings included:

  • Enhanced Mobility in Older Organisms: Subjects treated with Telomir-1 showed improved motility, particularly in later stages of life, compared to untreated controls. This enhanced movement in advanced age suggests a slowing of the aging process, as mobility is a key indicator of biological health.

  • Reduced Biological Aging: The study demonstrated a measurable reversal of biological age markers in subjects treated with Telomir-1. This significant finding points to Telomir-1's potential to slow down, and in certain aspects, reverse biological aging, making it a promising candidate for longevity treatments.

  • Increased Lifespan: Telomir-1 was associated with a statistically significant increase in lifespan among treated populations. This further supports Telomir-1's role in promoting longevity.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, elaborated: "This study confirms that Telomir-1 not only extends life but also supports healthier aging, as evidenced by improvements in mobility and reduced age-related decline. These findings establish a promising foundation for Telomir-1 as a transformative treatment in age-reversal science."

Expanding Research and Future Applications

Telomir is intensifying its focus on the potential use of Telomir-1 to treat progeria, a rare genetic disorder that causes accelerated aging in children. As part of these efforts, Telomir has engaged with the Progeria Foundation to investigate the effects of Telomir-1 on human progeria cell lines. This study will directly assess Telomir-1's ability to counteract accelerated aging at the cellular level, offering critical insights into its therapeutic potential for progeria patients.

In addition, Telomir has planned an in vivo study utilizing a progeria Caenorhabditis elegans model. This advanced microfluidic-based assay will evaluate Telomir-1's impact on longevity, healthspan, and biological aging in an organismal context. Together, these two studies represent a comprehensive approach to understanding Telomir-1's effects on progeria, targeting both cellular and whole-organism models of the disease.

These initiatives build on Telomir-1's demonstrated safety and efficacy in preclinical studies, which highlight its broad potential across various age-related conditions. Beyond progeria, Telomir is advancing research into chronic diseases such as diabetes, cancer, and inflammatory conditions. Ongoing discussions with a leading veterinary institution aim to establish a large-scale study on elderly dogs with osteoarthritis, further exploring Telomir-1's potential to improve joint health and mobility.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in age-reversal science. The Company is focused on the development of Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. The Company's goal is to explore the potential of Telomir-1 starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the anticipated benefits of the preclinical testing results described herein, (ii) anticipated timelines for additional preclinical and clinical testing of Telomir-1 and (iii) the potential therapeutic benefits of Telomir-1 generally.

Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of significant risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.

W.Knight--TFWP